ESSA Pharma (EPI) News Today Add Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA PharmaMarch 9, 2025 | markets.businessinsider.comSan Diego biotech gets FDA approval for epi-pen alternative for kidsMarch 6, 2025 | msn.comROSEN, LEADING TRIAL ATTORNEYS, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EPIXMarch 4, 2025 | markets.businessinsider.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA PharmaFebruary 21, 2025 | markets.businessinsider.comRTW INVESTMENTS, LP Reduces Stake in ESSA Pharma IncFebruary 14, 2025 | gurufocus.comEssa Pharma reports Q4 EPS (14c), consensus (27c)December 18, 2024 | markets.businessinsider.comESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trialsNovember 4, 2024 | msn.comEssa Pharma downgraded to Neutral from Overweight at Piper SandlerNovember 4, 2024 | markets.businessinsider.comESSA Pharma (NASDAQ:EPIX) Stock, Short Interest ReportNovember 3, 2024 | benzinga.comEssa Pharma Inc.November 1, 2024 | wsj.comESSA Pharma halts Phase II study of masofaniten in prostate cancer treatmentNovember 1, 2024 | msn.comESSA Stops Phase 2 Study Of Masofaniten Combo In Metastatic Castration-Resistant Prostate CancerOctober 31, 2024 | markets.businessinsider.comESSA Pharma (NASDAQ:EPIX) Stock Quotes, Forecast and News SummaryOctober 20, 2024 | benzinga.comOppenheimer Sticks to Their Buy Rating for ESSA Pharma (EPIX)September 16, 2024 | markets.businessinsider.comESSA Pharma (EPIX) Gets a Buy from Piper SandlerSeptember 16, 2024 | markets.businessinsider.comESSA Pharma Inc: ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO CongressSeptember 14, 2024 | finanznachrichten.dePiper Sandler Keeps Their Buy Rating on ESSA Pharma (EPIX)September 10, 2024 | markets.businessinsider.comBuy Rating Affirmed on ESSA Pharma Amid Promising mCRPC Therapy Data and Upcoming ESMO Conference InsightsSeptember 10, 2024 | markets.businessinsider.comFDA Approves ARS Pharma's Neffy Nasal Spray for Emergency Allergy TreatmentAugust 9, 2024 | marketwatch.comESSA Pharma Growth Prospects Bolstered by Promising Prostate Cancer Treatment DevelopmentsAugust 6, 2024 | markets.businessinsider.comEPIX ESSA Pharma Inc.July 24, 2024 | seekingalpha.comESSA Pharma's Speculative Buy Potential: Masofaniten Promise For Prostate CancerMay 29, 2024 | seekingalpha.comESSA Bancorp Inc ESSAMay 1, 2024 | morningstar.comDoes Insurance Cover EpiPens?April 27, 2024 | msn.comESSA Pharma Inc (EPIX)April 7, 2024 | uk.investing.comEssa Pharma initiated with bullish view at JonesResearch, here's whyJanuary 30, 2024 | realmoney.thestreet.comEPIX: Updated Data for Phase 1 Trial of Masofaniten Shows 63% of Patients Achieved PSA <0.2 ng/mL…January 26, 2024 | finance.yahoo.comWhat's Going On With Prostate Cancer Focused ESSA Pharma Stock Today?January 26, 2024 | msn.comESSA Pharma Inc: ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers SymposiumJanuary 25, 2024 | finanznachrichten.deESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers SymposiumJanuary 25, 2024 | finance.yahoo.comESSA Pharma Inc (EPIX) Reports Fiscal Q4 and Full-Year Earnings, Advances in Prostate Cancer ...December 12, 2023 | finance.yahoo.comDirector Franklin Berger Bolsters Position in ESSA Pharma Inc with Purchase of 23,259 SharesNovember 23, 2023 | finance.yahoo.comESSA Pharma: Unique N-Terminal Domain Approach Might Hinder mCRPC ResistanceNovember 7, 2023 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Regeneron (REGN), Akero Therapeutics (AKRO) and ESSA Pharma (EPIX)October 24, 2023 | markets.businessinsider.comProstate Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)October 6, 2023 | benzinga.comESSA Pharma files for $200M mixed shelf offering - filingSeptember 20, 2023 | seekingalpha.comOppenheimer Reiterates Essa Pharma (EPIX) Outperform RecommendationAugust 9, 2023 | msn.comWhy are EpiPens still so expensive?April 4, 2023 | msn.comESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)February 13, 2023 | finance.yahoo.comEPIX: Advancing Multiple Clinical Trials in 2023…December 19, 2022 | finance.yahoo.comESSA Pharma: EPI-7386+Xtandi Combination Has Shown Highest Efficacy In Metastatic, Castration-Resistant Prostate CancerNovember 16, 2022 | seekingalpha.comEssa Pharma Shares Drop 26% After Janssen Suspends Enrollment for TrialsOctober 31, 2022 | marketwatch.comESSA drops 26% as Johnson & Johnson ends trial enrollment for lead assetOctober 31, 2022 | seekingalpha.comESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR SymposiumOctober 26, 2022 | finance.yahoo.comESSA Pharma Surges 152% on Study Results for Lead Drug CandidateOctober 26, 2022 | marketwatch.comPromontory Therapeutics Reports PT-112's Effects on Human Prostate Cancer Cell Mitochondria at the 34th EORTC-NCI-AACR SymposiumOctober 26, 2022 | finance.yahoo.comESSA Pharma jumps 91% on Phase 1/2 data for prostate cancer therapyOctober 26, 2022 | seekingalpha.comEPIX: Multiple Ongoing Studies of EPI-7386…August 10, 2022 | finance.yahoo.comESSA Pharma's EPI-7386 Monotherapy / Combo Therapy Show Early Activity Against Prostate CancerJune 28, 2022 | finance.yahoo.comEpiEndo: Successful Completion of Phase I Study for Lead Asset EP395May 18, 2022 | apnews.com Get ESSA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EPI and its competitors with MarketBeat's FREE daily newsletter. Email Address EPI Media Mentions By Week EPI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EPI News Sentiment▼0.001.17▲Average News Sentiment EPI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EPI Articles This Week▼00▲EPI Articles Average Week Get ESSA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EPI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:EPI) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EPI Stock Free EPI Stock Alerts